Get the Stockscreener App
86.58
3.58%
2.99
After Hours:
87.02
0.44
+0.51%
Guardant Health Inc stock is traded at $86.58, with a volume of 2.15M.
It is up +3.58% in the last 24 hours and down -9.12% over the past month.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
See More
Previous Close:
$83.59
Open:
$85
24h Volume:
2.15M
Relative Volume:
1.12
Market Cap:
$11.36B
Revenue:
$982.02M
Net Income/Loss:
$-416.28M
P/E Ratio:
-26.12
EPS:
-3.3148
Net Cash Flow:
$-233.07M
1W Performance:
-0.79%
1M Performance:
-9.12%
6M Performance:
+43.87%
1Y Performance:
+86.35%
1-Day Range:
$84.51
$89.26
1-Week Range:
$82.39
$90.28
52-Week Range:
$36.36
$120.74
Guardant Health Inc Stock (GH) Company Profile
Name
Guardant Health Inc
Sector
Industry
Phone
855-698-8887
Address
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
86.58 | 10.96B | 982.02M | -416.28M | -233.07M | -3.3148 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Reiterated | Canaccord Genuity | Buy |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Jan-05-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Sep-25-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Sep-22-25 | Resumed | Wells Fargo | Overweight |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-28-24 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-24-24 | Resumed | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Sep-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-26-23 | Upgrade | Citigroup | Neutral → Buy |
| May-05-23 | Initiated | UBS | Buy |
| Mar-09-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Nov-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-22 | Initiated | Craig Hallum | Buy |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Apr-28-22 | Resumed | BTIG Research | Buy |
| Feb-24-22 | Reiterated | Canaccord Genuity | Buy |
| Feb-24-22 | Reiterated | Citigroup | Buy |
| Feb-24-22 | Reiterated | Cowen | Outperform |
| Feb-24-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-24-22 | Reiterated | SVB Leerink | Outperform |
| Feb-24-22 | Reiterated | Stifel | Buy |
| Feb-24-22 | Reiterated | Wells Fargo | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-11-21 | Initiated | Stifel | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jun-12-20 | Initiated | BTIG Research | Buy |
| Feb-21-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Aug-07-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-16-19 | Initiated | Canaccord Genuity | Buy |
| Apr-10-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-28-19 | Reiterated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | BofA/Merrill | Neutral |
| Oct-29-18 | Initiated | JP Morgan | Overweight |
| Oct-29-18 | Initiated | William Blair | Outperform |
View All
Guardant Health Inc Stock (GH) Latest News
Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia - MSN
Guardant Health Ignites 5.6% Surge: A Volatile Breakout or a Trap for the Unwary? - Bitget
Verana and Guardant’s RWE Stack Aims to Solve Precision Oncology’s Data Challenges—Driving Growth Through Recurring Revenue and Broader Data Collections - Bitget
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data - PR Newswire
Guardant Health Manulife Shield Partnership Highlights Asia Growth And Valuation Gap - Yahoo Finance
GH Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Multiple analysts lift Guardant Health, Inc. (GH) targets on screening and data growth - MSN
Insiders Shake Up Guardant, Ovintiv, Redwire, Builders FirstSource, Permian - TipRanks
Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view - MSN
Guardant Health (GH) Partners With Manulife to Launch Shield Multi-Cancer Detection Test in Asia - Insider Monkey
Guardant Health to present 28 abstracts on multiomic cancer research at AACR26 - Traders Union
Guardant Health, Inc. $GH Shares Sold by Polar Asset Management Partners Inc. - MarketBeat
GH Stock Price, Quote & Chart | GUARDANT HEALTH INC (NASDAQ:GH) - ChartMill
Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health (GH) director Tariq Musa sells $30,655 in stock By Investing.com - Investing.com Australia
Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock - MarketBeat
Guardant Health (GH) director Tariq Musa sells $30,655 in stock - Investing.com
Guardant Health (NASDAQ: GH) director sells 348 company shares - Stock Titan
3 Reasons to Steer Clear of GH and One Alternative Stock Worth Buying - Bitget
Guardant Health Stock Analysis: Price Rise vs. Financial Risks | 2026News and Statistics - IndexBox
3 Reasons to Avoid GH and 1 Stock to Buy Instead - Yahoo Finance
15 Most Promising Stocks Under $100 to Buy - Insider Monkey
(GH) Risk Channels and Responsive Allocation - Stock Traders Daily
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics - Investing.com
Director at Guardant Health (GH) receives 232 shares via RSUs - Stock Titan
Guardant Health (NASDAQ: GH) Form 144 shows proposed insider sale of shares - Stock Titan
Guardant Health launches multi-cancer blood test in Asia through Manulife partnership - Mugglehead Investment Magazine
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 - BioSpace
Guardant Health acquires MetaSight amid positive 2026 financial outlook - MSN
Why Guardant Health’s (GH) 2026 Screening Story Reinforced Piper Sandler’s Bullish View - Insider Monkey
Guardant Health (GH) Co-CEO logs RSU grants, tax withholding and trust share transfer - Stock Titan
Guardant Health (GH) Co-CEO receives RSUs and shifts shares to trust - Stock Titan
Guardant Health (NASDAQ:GH) CFO Sells $261,120.00 in Stock - MarketBeat
Guardant Health launches Shield Multi-Cancer Detection Test in APAC market - BioSpectrum Asia
Guardant Health (GH) director acquires 249 shares via RSU vesting - Stock Titan
Guardant Health (NASDAQ: GH) CLO gains stock through RSU vesting - Stock Titan
Guardant Health (GH) CIO exercises RSUs and PBRSUs; 6,839 shares withheld for taxes - Stock Titan
Guardant Health (GH) CCO gains shares through RSU vesting and tax withholding - Stock Titan
Guardant Health (GH) CMO exercises RSUs; shares withheld to cover taxes - Stock Titan
Guardant Health (GH) CTO exercises 10,714 PSUs; 5,759 shares withheld for taxes - Stock Titan
Guardant Health (GH) CFO sells shares and reports RSU vesting - Stock Titan
Survey Supports Blood Tests for Colorectal Cancer Screening - Cure Today
Here’s Why Artisan Small Cap Fund Bets on Guardant Health (GH) - Insider Monkey
Oncology Molecular Diagnostics Market Growth 2026 | NGS, PCR - openPR.com
Singapore's Guardant Health launches Shield Multi-Cancer Detection (MCD) Test in APAC market - BioSpectrum Asia
Guardant Health Touts Quest Deal for Shield, Guardant360 Growth and FDA Milestones at Leerink Conference - MarketBeat
Algert Global LLC Raises Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health Touts Hypergrowth in Guardant360, Reveal MRD and Shield CRC at Barclays Conference - MarketBeat
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health, Harris Poll Survey Shows 92% of Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered - National Today
Guardant Health, Inc. $GH Shares Bought by Iron Triangle Partners LP - MarketBeat
Guardant Health Inc Stock (GH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):